U.S. flag

An official website of the United States government

NM_005343.4(HRAS):c.189G>C (p.Glu63Asp) AND Costello syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Feb 20, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002705677.3

Allele description [Variation Report for NM_005343.4(HRAS):c.189G>C (p.Glu63Asp)]

NM_005343.4(HRAS):c.189G>C (p.Glu63Asp)

Genes:
HRAS:HRas proto-oncogene, GTPase [Gene - OMIM - HGNC]
LRRC56:leucine rich repeat containing 56 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11p15.5
Genomic location:
Preferred name:
NM_005343.4(HRAS):c.189G>C (p.Glu63Asp)
HGVS:
  • NC_000011.10:g.533867C>G
  • NG_007666.1:g.6684G>C
  • NG_121454.1:g.176C>G
  • NM_001130442.3:c.189G>C
  • NM_001318054.2:c.-131G>C
  • NM_005343.4:c.189G>CMANE SELECT
  • NM_176795.5:c.189G>C
  • NP_001123914.1:p.Glu63Asp
  • NP_005334.1:p.Glu63Asp
  • NP_789765.1:p.Glu63Asp
  • LRG_506t1:c.189G>C
  • LRG_506:g.6684G>C
  • LRG_506p1:p.Glu63Asp
  • NC_000011.9:g.533867C>G
Protein change:
E63D
Molecular consequence:
  • NM_001318054.2:c.-131G>C - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001130442.3:c.189G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_005343.4:c.189G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_176795.5:c.189G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Costello syndrome (CSTLO)
Synonyms:
Faciocutaneoskeletal syndrome; FCS syndrome
Identifiers:
MONDO: MONDO:0009026; MedGen: C0587248; Orphanet: 3071; OMIM: 218040

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002998643Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Feb 20, 2022)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation.

van der Burgt I, Kupsky W, Stassou S, Nadroo A, Barroso C, Diem A, Kratz CP, Dvorsky R, Ahmadian MR, Zenker M.

J Med Genet. 2007 Jul;44(7):459-62. Epub 2007 Apr 5.

PubMed [citation]
PMID:
17412879
PMCID:
PMC2598013

Congenital muscular dystrophy phenotype with neuromuscular spindles excess in a 5-year-old girl caused by HRAS mutation.

Bolocan A, Quijano-Roy S, Seferian AM, Baumann C, Allamand V, Richard P, Estournet B, Carlier R, Cavé H, Gartioux C, Blin N, Le Moing AG, Gidaro T, Germain DP, Fardeau M, Voit T, Servais L, Romero NB.

Neuromuscul Disord. 2014 Nov;24(11):993-8. doi: 10.1016/j.nmd.2014.06.437. Epub 2014 Jun 28.

PubMed [citation]
PMID:
25070542
See all PubMed Citations (4)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002998643.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Glu63 amino acid residue in HRAS. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17412879, 25070542, 26001911). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt HRAS protein function. This variant has not been reported in the literature in individuals affected with HRAS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 63 of the HRAS protein (p.Glu63Asp).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024